On Friday, UniPixel Inc (NASDAQ:UNXL)’s shares declined -6.94% to $7.11.
UniPixel Inc (UNXL) has attained, through its wholly owned partner, Uni-Pixel Displays, Inc., the assets of Atmel Corporation’s XSense® touch sensors group, and has co presently reached patent and intellectual property licenses with Atmel, exclusive for a period of two years, for the use of XSense-related technologies.
UniPixel also has attained separate licenses for fine line technology from Atmel’s partner, CIT Technology Limited, a wholly owned partner of Carclo plc (LSE: CAR). The licenses with CIT Technology as to the products covered by the patents and intellectual property being licensed are also exclusive for a period of two years.
Uni-Pixel, Inc., a pre-production stage company, engages in developing performance engineered film (PEF) products for the display, touch screen, and flexible electronics market segments in the United States.
McDermott International (NYSE:MDR)’s shares dropped -6.90% to $5.13.
McDermott International (MDR) declared that the consortium between McDermott and a consortium partner has been awarded the SURF engineering, product supply and installation scope for the Atlanta Early Production System (EPS) in the Santos Basin offshore Brazil by Brazilian exploration and Production Company Queiroz Galvão Exploração e Produção S.A. (QGEP).
McDermott engineering and installation revenue from the large, green field project will be comprised of in backlog for the first quarter of 2015. The project is predictable to be accomplished by the end of the second quarter of 2016.
McDermott International, Inc. operates as an engineering, procurement, construction, and installation company worldwide. The company operates through three segments: Asia Pacific, Americas, and the Middle East. It focuses on designing and executing offshore oil and gas projects.
At the end of Friday’s trade, Antares Pharma Inc (NASDAQ:ATRS)‘s shares dipped -6.73% to $2.77.
Antares Pharma Inc (ATRS) declared that it has settled all litigation between Antares and Medac Pharma, Inc. and its parent, medac GmbH. Following the settlement contract, the parties will dismiss proceedings related to their respective patents pending before the United States District Court for the District of Delaware, the United States District Court for the District of New Jersey, the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office, and the Technical Board of Appeal of the European Patent Office. The settlement contract also provides for a royalty-free cross-license under the patents-in-suit and their families allowing the manufacture and sale of OTREXUP(TM) and RASUVO(TM) in and for the U.S.
Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide.
EXCO Resources Inc (NYSE:XCO), ended its Friday’s trading session with -6.64% loss, and closed at $2.11.
EXCO Resources Inc (XCO) declared that it will be releasing first quarter 2015 results on Tuesday, April 28, 2015, after market close.
EXCO will host a conference call on Wednesday, April 29, 2015, at 9:00 a.m. (Central Time) to talk about the contents of this release and respond to questions.
EXCO Resources, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and production of onshore oil and natural gas properties with a focus on shale resource plays in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
